Press Releases April 23, 2026 06:30 AM

BOSS Zhipin's Ongoing Share Repurchases Exceed RMB985 Million in 2026

KANZHUN LIMITED (BOSS Zhipin) surpasses RMB985 million in share repurchases in 2026, reaffirming shareholder value focus.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (BOSS Zhipin) announced continued execution of its share repurchase program, having spent over RMB985 million year-to-date in 2026, including RMB27.2 million used to buy back 580,426 shares on April 22. The company signals its strong commitment to enhancing shareholder returns through this significant buyback activity.

BOSS Zhipin's Ongoing Share Repurchases Exceed RMB985 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BOSS Zhipin has repurchased over RMB985 million worth of shares so far in 2026.
  • On April 22, 2026, the company bought back 580,426 shares utilizing RMB27.2 million.
  • The sustained share repurchase program highlights the company’s focus on enhancing shareholder value.

BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.2 million to repurchase 580,426 ordinary shares on April 22. Year-to-date in 2026, the Company has deployed over RMB985 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued share buybacks could impact the company’s cash reserves and liquidity.
  • Market conditions may affect the effectiveness of repurchases in boosting share price.
  • Potential regulatory or market fluctuations might influence future buyback execution.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026